Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Vanda reported Q2 2026 total net product sales of $50.5 million, a 4% decrease from the prior year, with a net loss of $62.5 million or $1.04 per share driven by increased operating expenses for product launches and pipeline advancement. Despite the overall revenue decline, the company's lead product Fanapt grew sales 23% to $36.0 million, and Vanda reiterated its full-year 2026 revenue guidance of $240 million to $290 million.
Key figures
- Revenue
- 50500000
- Guidance
- $240 to $290 million
- Revenue Yoy
- -4%
- Cash
- 170000000
- Net loss
- 62500000
- Cash burn q2
- 32300000
- Fanapt sales
- 36000000
- Operating expenses
- 114338000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.